English Journal

Uratsuji H1, Nakamura A, Yamada Y, Hashimoto K, Matsumoto T, Ikeda F, Ishii R.
Mycoses.Mycoses.2015 Apr;58(4):197-202. doi: 10.1111/myc.12297. Epub 2015 Feb 10.
Topical antifungal agents which have anti-inflammatory effects have the potential to provide additional clinical benefits. Therefore, an anti-inflammatory activity of lanoconazole (LCZ), a topical antifungal agent, was investigated against in vitro and in vivo models of inflammation. The release of
PMID 25675966

Khanna D1, Bharti S1.
Core evidence.Core Evid.2014 Sep 24;9:113-24. doi: 10.2147/CE.S49629. eCollection 2014.
Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this review, we summariz
PMID 25285056

Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study.

Jarratt M1, Jones T, Kempers S, Rich P, Morton K, Nakamura N, Tavakkol A.
Cutis.Cutis.2013 Apr;91(4):203-10.
Tinea pedis (TP) typically is treated with topical antifungal agents. Luliconazole, a novel imidazole drug, is shown to be as or more effective in vitro and in vivo than bifonazole, terbinafine, and lanoconazole. Two treatment durations with luliconazole cream 1% were evaluated for treatment of TP.
PMID 23763082